

![]() |
Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective |
|
Authors | ||
Published in | Clinical Microbiology and Infection. 2017, vol. 23, no. 9, p. 659-666 | |
Abstract | Few industry-independent studies have been conducted to compare the relative costs and benefits of drugs to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies-linezolid versus trimethoprim-sulfamethoxazole plus rifampicin-for the treatment of MRSA infection. | |
Identifiers | PMID: 28232163 | |
Full text | ||
Structures | ||
Research group | Groupe Harbarth Stephan (Staphylocoques dorés résistants à la méthicilline) (866) | |
Citation (ISO format) | VON DACH, Elodie et al. Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. In: Clinical Microbiology and Infection, 2017, vol. 23, n° 9, p. 659-666. doi: 10.1016/j.cmi.2017.02.011 https://archive-ouverte.unige.ch/unige:99033 |